PURPOSE:Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown. PATIENTS AND METHODS: Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP). Responding patients received high-dose chemotherapy and ASCT. RESULTS:The median age of the 396 patients enrolled (R-ICE, n = 202; R-DHAP, n = 194) was 55 years. Similar response rates were observed after three cycles of R-ICE (63.5%; 95% CI, 56% to 70%) and R-DHAP (62.8%; 95 CI, 55% to 69%). Factors affecting response rates (P < .001) were refractory disease/relapse less than versus more than 12 months after diagnosis (46% v 88%, respectively), International Prognostic Index (IPI) of more than 1 versus 0 to 1 (52% v 71%, respectively), and prior rituximab treatment versus no prior rituximab (51% v 83%, respectively). There was no significant difference between R-ICE and R-DHAP for 3-year event-free survival (EFS) or overall survival. Three-year EFS was affected by prior rituximab treatment versus no rituximab (21% v 47%, respectively), relapse less than versus more than 12 months after diagnosis (20% v 45%, respectively), and IPI of 2 to 3 versus 0 to 1 (18% v 40%, respectively). In the Cox model, these parameters were significant (P < .001). CONCLUSION: In patients who experience relapse more than 12 months after diagnosis, prior rituximab treatment does not affect EFS. Patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.
RCT Entities:
PURPOSE: Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown. PATIENTS AND METHODS: Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP). Responding patients received high-dose chemotherapy and ASCT. RESULTS: The median age of the 396 patients enrolled (R-ICE, n = 202; R-DHAP, n = 194) was 55 years. Similar response rates were observed after three cycles of R-ICE (63.5%; 95% CI, 56% to 70%) and R-DHAP (62.8%; 95 CI, 55% to 69%). Factors affecting response rates (P < .001) were refractory disease/relapse less than versus more than 12 months after diagnosis (46% v 88%, respectively), International Prognostic Index (IPI) of more than 1 versus 0 to 1 (52% v 71%, respectively), and prior rituximab treatment versus no prior rituximab (51% v 83%, respectively). There was no significant difference between R-ICE and R-DHAP for 3-year event-free survival (EFS) or overall survival. Three-year EFS was affected by prior rituximab treatment versus no rituximab (21% v 47%, respectively), relapse less than versus more than 12 months after diagnosis (20% v 45%, respectively), and IPI of 2 to 3 versus 0 to 1 (18% v 40%, respectively). In the Cox model, these parameters were significant (P < .001). CONCLUSION: In patients who experience relapse more than 12 months after diagnosis, prior rituximab treatment does not affect EFS. Patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.
Authors: W S Velasquez; F Cabanillas; P Salvador; P McLaughlin; M Fridrik; S Tucker; S Jagannath; F B Hagemeister; J R Redman; F Swan Journal: Blood Date: 1988-01 Impact factor: 22.113
Authors: Paul A Hamlin; Andrew D Zelenetz; Tarun Kewalramani; Jing Qin; Jaya M Satagopan; David Verbel; Ariela Noy; Carol S Portlock; David J Straus; Joachim Yahalom; Stephen D Nimer; Craig H Moskowitz Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544
Authors: Issa F Khouri; Rima M Saliba; Chitra Hosing; Grace-Julia Okoroji; Sandra Acholonu; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Michele L Donato; Luis Fayad; Segio Giralt; Roy Jones; Martin Korbling; Farzaneh Maadani; John T Manning; Barbara Pro; Elizabeth Shpall; Anas Younes; Peter McLaughlin; Richard E Champlin Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: Tarun Kewalramani; Andrew D Zelenetz; Stephen D Nimer; Carol Portlock; David Straus; Ariela Noy; Owen O'Connor; Daniel A Filippa; Julie Teruya-Feldstein; Alison Gencarelli; Jing Qin; Alyson Waxman; Joachim Yahalom; Craig H Moskowitz Journal: Blood Date: 2004-01-22 Impact factor: 22.113
Authors: J Blay; F Gomez; C Sebban; T Bachelot; P Biron; C Guglielmi; A Hagenbeek; R Somers; F Chauvin; T Philip Journal: Blood Date: 1998-11-15 Impact factor: 22.113
Authors: T Philip; J O Armitage; G Spitzer; F Chauvin; S Jagannath; J Y Cahn; P Colombat; A H Goldstone; N C Gorin; M Flesh Journal: N Engl J Med Date: 1987-06-11 Impact factor: 91.245
Authors: C Guglielmi; F Gomez; T Philip; A Hagenbeek; M Martelli; C Sebban; N Milpied; D Bron; J Y Cahn; R Somers; P Sonneveld; C Gisselbrecht; H Van Der Lelie; F Chauvin Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544
Authors: Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht Journal: Blood Date: 2017-08-03 Impact factor: 22.113
Authors: Mehdi Hamadani; Wael Saber; Kwang Woo Ahn; Jeanette Carreras; Mitchell S Cairo; Timothy S Fenske; Robert Peter Gale; John Gibson; Gregory A Hale; Parameswaran N Hari; Jack W Hsu; David J Inwards; Rammurti T Kamble; Anderas Klein; Dipnarine Maharaj; David I Marks; David A Rizzieri; Bipin N Savani; Harry C Schouten; Edmund K Waller; Baldeep Wirk; Ginna G Laport; Silvia Montoto; David G Maloney; Hillard M Lazarus Journal: Biol Blood Marrow Transplant Date: 2013-02-01 Impact factor: 5.742
Authors: Victor A Chow; Ajay K Gopal; David G Maloney; Cameron J Turtle; Stephen D Smith; Chaitra S Ujjani; Mazyar Shadman; Ryan D Cassaday; Brian G Till; Yolanda D Tseng; Edus H Warren; Andrei R Shustov; Manoj P Menon; Sandra Bhark; Utkarsh H Acharya; Erin Mullane; Lindsay M Hannan; Jenna M Voutsinas; Ted A Gooley; Ryan C Lynch Journal: Am J Hematol Date: 2019-05-21 Impact factor: 10.047
Authors: Craig S Sauter; Joanne F Chou; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; James W Young; Michael Scordo; Sergio Giralt; Hugo Castro-Malaspina Journal: Leuk Lymphoma Date: 2014-03-20
Authors: Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass Journal: J Clin Oncol Date: 2012-10-22 Impact factor: 44.544